← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Gallium Ga 68 dotatate

FDA approved · Rx

Radiolabeled somatostatin analog imaging agent

Also known as: Netspot, 68Ga-DOTATATE, Gallium 68 DOTA-octreotide, 68gallium-DOTA-Tyr(3)-Thr(8)-octreotate, Dotatate gallium Ga-68, Gatate, Gallium 68 dotatate

Evidence score
92/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 108 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Gallium Ga 68 dotatate is a diagnostic radiopharmaceutical made of a somatostatin-like peptide (octreotate) linked by a DOTA chelator to the radioactive isotope gallium-68. It binds to somatostatin receptors, especially subtype 2, which are often abundant on neuroendocrine tumor cells, allowing those tumors to be seen on PET scans. It is an imaging tool, not a treatment.

What the evidence shows

Automatic summaryHuman trials

Marketed as Netspot, it is approved for PET imaging to locate somatostatin receptor positive neuroendocrine tumors in adults and children, supported by more than 100 registered human trials reaching Phase 4. It has no established therapeutic effect. The supplied database record did not confirm the FDA brand listing, although the regulatory status is recorded as prescription approved.

Key facts

Molecular formula
C65H87GaN14O19S2
Molecular weight
1500.5 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

108registered studies
Phase 4most advanced phase
37completed (sample)
27recruiting (sample)

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

Phase 2CompletedNCT03125629

Biomarker Study of Pancreatic Neuroendocrine Tumours

UnknownNCT03741517

The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT

CompletedNCT05730634

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

No Longer AvailableNCT01980732

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

7papers referencing Gallium Ga 68 dotatate

The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.

Turk J Med Sci2016

Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers-a review of clinical studies.

Endocrine2024

Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.

BMJ Case Rep2024

Neuroendocrine Tumor of Unknown Origin Leading to the Diagnosis of Advanced Celiac Disease: A Case Report Exploring a Possible Association.

Case Rep Gastroenterol2026

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.